All In Biotech

Drug Trial Radar · NCT07169942

Aleniglipron Phase 2 Body Composition Study

A Phase 2, Randomized, Double-blind, Placebo-controlled, Study Evaluating the Effects of Aleniglipron (GSBR-1290) on Body Composition in Participants Living With Obesity (Body Mass Index ≥ 30 kg/m2)

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

71

Actual

Start

Aug 15, 2025

Primary completion

Sep 9, 2026

Study completion Sep 10, 2026

Sponsor

Sponsor type
Industry
First posted
Sep 12, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 79 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is a randomized, double-blind, placebo-controlled study evaluating the effects of aleniglipron on body composition in participants living with obesity. Participants will be randomized to aleniglipron or placebo in a ratio of 5:1. Participants will receive multiple ascending QD doses of aleniglipron or placebo in titration steps of 4 weeks duration for a total of 44 weeks of treatment.

Conditions

  • Obesity, Overweight, or Chronic Weight Management

Interventions

  • aleniglipron or placeboDrug

    Drug: aleniglipron administered orally Drug: placebo administered orally

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change in total body fat mass by DXATime frame: Baseline and week 44

Locations

11 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Phoenix, Arizona

  • Research Site

    Chicago, Illinois

  • Research Site

    Richfield, Minnesota

  • Research Site

    City of Saint Peters, Missouri

  • Research Site

    Rochester, New York

  • Research Site

    Wilmington, North Carolina

  • Research Site

    Norman, Oklahoma

  • Research Site

    Moncks Corner, South Carolina

  • Research Site

    North Charleston, South Carolina

  • Research Site

    Austin, Texas

  • Research Site

    San Antonio, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.